Azafaros

News

Azafaros is set to start phase 3 trials of its lead drug for a trio of rare lysosomal storage disorders, backed by €132m in new Series B financing.

News

Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.